Viracta Therapeutics Inc. Watch

from 10-Q 3 pages First Amendment to Lease Between Plastino II, LP and Viracta Therapeutics, Inc

from 10-Q 6 pages Viracta Therapeutics, Inc. Outside Director Compensation Policy

from 8-K 13 pages Viracta Therapeutics, Inc. Executive Employment Agreement This Employment Agreement (This “Agreement”) by and Between Viracta Therapeutics, Inc. (The “Company”) and Michael E. Faerm (“Executive”) Is Effective as of May 13, 2024 (The “Effective Date”). 1. Duties and Scope of Employment

from 10-Q 7 pages Consulting Agreement

from 8-K 16 pages Viracta Therapeutics, Inc. Executive Employment Agreement

from 10-K 4 pages Amendment No. 1 to Royalty Purchase Agreement

from 10-K 4 pages Amendment No. 1 to License Agreement for Raf

from 10-K 26 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private and Confidential. License Agreement for Raf

from 10-Q 13 pages Viracta Therapeutics, Inc. Executive Employment Agreement This Employment Agreement (This “Agreement”) by and Between Viracta Therapeutics, Inc. (The “Company”) and Darrel P. Cohen, M.D., PH.D. (“Executive”) Is Effective as of August 7, 2023 (The “Effective Date”). 1. Duties and Scope of Employment

from 10-Q 2 pages First Amendment to Lease Between Plastino II, LP and Viracta Therapeutics, Inc

from 10-Q 5 pages Viracta Therapeutics, Inc. Outside Director Compensation Policy

from 8-K/A 6 pages Certain Confidential Information Contained in This Document Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Has Been Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Consulting Agreement

from 8-K 13 pages Separation Agreement and Release

from 8-K 38 pages Viracta Therapeutics, Inc. Executive Employment Agreement

from 8-K 14 pages Viracta Therapeutics, Inc. 2022 Employee Stock Purchase Plan

from 10-K 7 pages Viracta Therapeutics, Inc. Executive Incentive Compensation Plan 1. Purposes of the Plan. the Plan Is Intended to Increase Stockholder Value and the Success of the Company by Motivating Employees to (A) Perform to the Best of Their Abilities and (B) Achieve the Company’s Objectives. 2. Definitions. 2.1 “Actual Award” Means as to Any Performance Period, the Actual Award (If Any) Payable to a Participant for the Performance Period, Subject to the Authority of the Administrator (As Defined in Section 3) Under Section 4.4. 2.2 “Affiliate” Means Any Corporation or Other Entity (Including, but Not Limited To, Partnerships and Joint Ventures) That, From Time to Time and at the Time of Any Determination, Directly or Indirectly, Is in Control of or Is Controlled by the Company. 2.3 “Board” Means the Board of Directors of the Company. 2.4 “Bonus Pool” Means the Pool of Funds Available for Distribution to Participants. Subject to the Terms of the Plan, the Administrator Establishes the Bonus Pool for Each Performance Period

from 8-K 6 pages Mutual Termination Agreement

from 10-Q 5 pages Viracta Therapeutics, Inc. Amendment to Employment Agreement

from 10-Q 5 pages Viracta Therapeutics, Inc. Amendment to Employment Agreement

from 10-Q 5 pages Viracta Therapeutics, Inc. Amendment to Employment Agreement